Equivalents Unchained


The Actavis v Eli Lilly decision of the UK Supreme Court has been described by some commentators as being a minor gloss on the law of patent infringement and claim scope.

07 December 2017

Deconstructing Actavis v Eli Lilly


The Supreme Court's decision in Actavis v Eli Lilly [2017] UKSC 48 has changed the way that the UK courts will determine the extent of protection of a patent's claim. Prior to this decision, since the House of Lords' decision in Catnic Components v Hill ...

13 October 2017

Recent Developments in Singapore's Patents Scene


The Intellectual Property Office of Singapore ("IPOS") has officially launched the Patents Open Dossier and Patents Formalities Manual to provide the public with better access to patent information

11 August 2017

Humira/adalimumab litigation confirms Arrow declarations' availability


Litigation centred on the antibody adalimumab (marketed as Humira by AbbVie and indicated for psoriasis and some forms of arthritis) has confirmed the ability to obtain so-called Arrow declarations in the English courts.

24 July 2017

Actavis v Eli Lilly – Summary of Supreme Court Decision of 12 July 2017


The United Kingdom Supreme Court (UKSC) today handed down its judgment in the case of Actavis UK Limited and others v Eli Lilly and Company ([2017] UKSC 46) that has significantly changed the law of patent infringement in the UK.

12 July 2017